You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
NEW YORK — Skin cancer test developer Castle Biosciences said today that it has priced its planned initial public offering at $16 a share, the top end of the previously disclosed range.
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?Login Now.
Don't have a 360Dx or GenomeWeb account?Register for Free.
Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.